Please assess the completion status of the following clinical trial:

Trial Title: Trial to Understand Efficacy of Colesevelam in Diarrhea Predominant IBS Patients With Bile Acid Malabsorption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females and males age 18 -75.~* An IBS diagnosis based on the Rome III criteria for at least 3 months, with onset at least 6 months previously, of recurrent abdominal pain or discomfort.~* Biomarkers serum alpha C4 ≥ 40 ng/mL or FGF19 ≤ 80 pg/mL or fecal bile acid \>2000 micromoles/48h~Exclusion Criteria:~* IBS patients with known clinically-relevant inflammation.~* IBS patient with known bleeding diathesis~* History of abdominal surgery~Patients participating will not take any of the following disallowed medications for at least 7 days prior to and during the remainder of the study:~* Any treatment specifically taken for IBS-D, including loperamide, cholestyramine, alosetron~* Drugs with a known pharmacological activity at 5-HT4, 5-HT2b or 5-HT3 receptors~* All narcotics~* Anti-cholinergic agents~* Tramadol~* Oral anticoagulants~* Antimuscarinics~* Peppermint oil~* Systemic antibiotics, as well as antibiotics directed at colonic flora such as rifaximin and metronidazole~Gastrointestinal preparations:~* Anti-nausea agents~* Osmotic laxative agents~* Prokinetic agents~* 5-HT3 antagonists

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Colesevelam (Type: ACTIVE_COMPARATOR): Once randomized, subjects will have baseline testing period, treatment period, and treatment testing period the study drug. This consists of nine visits and will be over a period of five to nine weeks.~Baseline testing period consists of: transit test, 4 day high fat diet with 48 hour stool collection, blood samples, rectosigmoid biopsies, one week stool diary, and medication pick up.~Treatment period will have subject take the study drug 1875 mg of medication orally twice daily with lunch and supper for 4-5 weeks.~The last period, is the treatment testing period. This consists of a full transit \& urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused medication.
- Placebo (Type: PLACEBO_COMPARATOR): Once randomized, subjects will have a baseline testing period, treatment period and treatment testing period with the placebo. This consists of nine visits and will be over a period of five to nine weeks.~The last period, is the treatment testing period. This consists of a full transit \& urine permeability test, 4 day high fat diet with 48 hour stool collection, blood samples, one week stool diary collection, and the return of the unused placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).